Nasal calcitonin for treatment of established osteoporosis.

Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS

Clinical endocrinology1 Apr 1989Cited by 110 (Europe PMC)

PMID2688995DOI10.1111/j.1365-2265.1989.tb00443.xPepBankPUB-02688995

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialActivity measurement
In women with osteoporosis, bone resorption estimates decreased during salmon calcitonin treatment (P less than 0.001).
In plain wordsIn women with osteoporosis, bone resorption estimates decreased during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
DecreaseBone resorption estimates
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · nasal · one yearAs given in this study (human).
Measurements
P value
< 0.001
calcitonin group
Source sentences
Summary
The biochemical estimates of both bone resorption and bone formation decreased highly significantly in the calcitonin group (P less than 0.001) and were unchanged in the control group, whereas the placebo (calcium) group showed intermediate values.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven women with established osteoporosis completed a one-year double-blind, placebo-controlled study with the primary aim of examining the effect of nasal salmon calcitonin (200 IU daily) on bone and calcium metabolism.
Summary · context
All the women received a daily calcium supplement of 500 mg.
Report a problemFND-0268899503
02HumanNon-randomized trialActivity measurement
In women with osteoporosis, bone formation estimates decreased during salmon calcitonin treatment (P less than 0.001).
In plain wordsIn women with osteoporosis, bone formation estimates decreased during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
DecreaseBone formation estimates
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · nasal · one yearAs given in this study (human).
Measurements
P value
< 0.001
calcitonin group
Source sentences
Summary
The biochemical estimates of both bone resorption and bone formation decreased highly significantly in the calcitonin group (P less than 0.001) and were unchanged in the control group, whereas the placebo (calcium) group showed intermediate values.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven women with established osteoporosis completed a one-year double-blind, placebo-controlled study with the primary aim of examining the effect of nasal salmon calcitonin (200 IU daily) on bone and calcium metabolism.
Summary · context
All the women received a daily calcium supplement of 500 mg.
Report a problemFND-0268899504
03HumanNon-randomized trialSafety outcome
In women with osteoporosis, no subjective side effects occurred during salmon calcitonin treatment.
In plain wordsIn women with osteoporosis, no subjective side effects occurred during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
Not applicableSubjective side effects
Study
n = 17
Outcome group
Adverse events · Whole body
Studied dose
200 IU daily · nasal · one yearAs given in this study (human).
Source sentences
Summary
Neither subjective nor objective side-effects occurred in any of the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven women with established osteoporosis completed a one-year double-blind, placebo-controlled study with the primary aim of examining the effect of nasal salmon calcitonin (200 IU daily) on bone and calcium metabolism.
Summary · context
All the women received a daily calcium supplement of 500 mg.
Report a problemFND-0268899505
04HumanNon-randomized trialSafety outcome
In women with osteoporosis, no objective side effects occurred during salmon calcitonin treatment.
In plain wordsIn women with osteoporosis, no objective side effects occurred during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
Not applicableObjective side effects
Study
n = 17
Outcome group
Adverse events · Whole body
Studied dose
200 IU daily · nasal · one yearAs given in this study (human).
Source sentences
Summary
Neither subjective nor objective side-effects occurred in any of the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven women with established osteoporosis completed a one-year double-blind, placebo-controlled study with the primary aim of examining the effect of nasal salmon calcitonin (200 IU daily) on bone and calcium metabolism.
Summary · context
All the women received a daily calcium supplement of 500 mg.
Report a problemFND-0268899506
05HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, the nasal salmon calcitonin group did not lose forearm bone mineral in comparison with the placebo and healthy control groups (P less than 0.01).
In plain wordsIn women with osteoporosis, the nasal salmon calcitonin group did not lose forearm bone mineral in comparison with the placebo and healthy control groups.
Peptide
Calcitonin-salmon
Outcome
IncreaseForearm bone mineral preservation
Study
n: not reported in source
Comparator
Placebo (calcium) group and age-matched healthy control group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · nasal · one yearAs given in this study (human).
Measurements
P value
< 0.01
calcitonin versus placebo and control groups
Source sentences
Summary
The calcitonin group (n = 17) did not lose bone mineral in comparison with the placebo (n = 20) and the control groups (n = 19) (P less than 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
The bone mineral measured in the forearm (single photon absorptiometry) and spine (dual photon absorptiometry) showed a similar pattern during treatment.
Summary · context
Thirty-seven women with established osteoporosis completed a one-year double-blind, placebo-controlled study with the primary aim of examining the effect of nasal salmon calcitonin (200 IU daily) on bone and calcium metabolism.
Summary · context
All the women received a daily calcium supplement of 500 mg.
Report a problemFND-0268899501
06HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, the nasal salmon calcitonin group did not lose spine bone mineral in comparison with the placebo and healthy control groups (P less than 0.01).
In plain wordsIn women with osteoporosis, the nasal salmon calcitonin group did not lose spine bone mineral in comparison with the placebo and healthy control groups.
Peptide
Calcitonin-salmon
Outcome
IncreaseSpine bone mineral preservation
Study
n: not reported in source
Comparator
Placebo (calcium) group and age-matched healthy control group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · nasal · one yearAs given in this study (human).
Measurements
P value
< 0.01
calcitonin versus placebo and control groups
Source sentences
Summary
The calcitonin group (n = 17) did not lose bone mineral in comparison with the placebo (n = 20) and the control groups (n = 19) (P less than 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
The bone mineral measured in the forearm (single photon absorptiometry) and spine (dual photon absorptiometry) showed a similar pattern during treatment.
Summary · context
Thirty-seven women with established osteoporosis completed a one-year double-blind, placebo-controlled study with the primary aim of examining the effect of nasal salmon calcitonin (200 IU daily) on bone and calcium metabolism.
Summary · context
All the women received a daily calcium supplement of 500 mg.
Report a problemFND-0268899502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.